Clinical Trials Logo
  1. Home
  2. MDD
  3. NCT05528315

SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects

MDD Clinical Trial

Official title:
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects

Clinical Trial Summary

The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-ascending doses (SAD) and multiple ascending doses (MAD) of ABX-002 in healthy volunteers (HV)

Clinical Trial Description

The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single-ascending doses (SAD) and multiple ascending doses (MAD) of ABX-002 in healthy volunteers (HV) to identify repeated dose levels that are safe and well-tolerated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05528315
Study type Interventional
Source Autobahn Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date October 12, 2022
Completion date September 13, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04482296 - Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients N/A
Recruiting NCT04071886 - Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study N/A
Completed NCT04076644 - Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder N/A
Recruiting NCT05437588 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents N/A
Recruiting NCT06095778 - rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS N/A
Active, not recruiting NCT05657691 - Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) Phase 2
Completed NCT02013609 - Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment Phase 3
Completed NCT02339285 - Transcranial Alternating Current Stimulation for Major Depressive Disorder N/A
Recruiting NCT03971305 - A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Recruiting NCT05169346 - Neurofeedback to Treat Depression N/A
Completed NCT01344733 - A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) N/A
Completed NCT04268316 - Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder N/A
Active, not recruiting NCT01557946 - Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression Phase 2
Recruiting NCT01501812 - Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders N/A
Completed NCT04880460 - Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients Phase 2
Completed NCT04226352 - Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder Phase 1
Recruiting NCT03754712 - Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder N/A
Recruiting NCT02669030 - A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Phase 4
Completed NCT03994081 - Mechanism of Action of tACS for the Treatment of MDD N/A
Completed NCT01152554 - A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder Phase 3